Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity
AssigneesThe United States of America, as represented by the Secretary, Dept. of Health and Human Services, The University of Birmingham Edgbaston
InventorsJay A . Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
Life of this patent
Estimating the term…
Abstract
β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.
Claims29
A composition comprising a β-mannosylceramide (β-ManCer) or salt or solvate thereof in a pharmaceutically acceptable carrier, wherein the β-ManCer comprises:
- a) a sphingosine moiety;
- and
- b) a fatty acid moiety comprising a linear or branched, saturated or unsaturated, aliphatic hydrocarbon group having from about 8 to about 49 carbon atoms.
(canceled)
19-20. (canceled)
23-24. (canceled)
A method of making β-ManCer, the method comprising reacting 2-amino-1-O-β-mannopyranosyl-D-ribo-1,3,4-octadecanetriol with an electrophile to form β-ManCer.
Dependencies are inferred from the claim text.